PD-L1 imaging with [^99mTc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancer.

ABSTRACT:

Background

Programmed death-ligand 1 (PD-L1) immunohistochemistry is a predictive biomarker for anti-PD-(L)1 therapy in non-small cell lung cancer (NSCLC). It is not a reliable predictor of clinical benefit with non-invasive imaging providing a potential solution. We present the PECan study, the aim of which to assess the relationship of [^99mTc]-labeled anti-PD-L1 single-domain antibody (NM-01) single-photon emission computed tomography (SPECT)/CT with metabolic response to anti-PD-(L)1.

Methods

PD-L1 tumour proportion score (TPS) measured using SP263 assay. [^99mTc]NM-01 SPECT/CT and [¹⁸F]FDG PET/CT performed before and 9-weeks following pembrolizumab with/without chemotherapy in patients with advanced NSCLC. Tumor (T) to blood pool (BP) maxi

SUBMITTER: Hughes DJ 

PROVIDER: S-EPMC12081918 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature